Drugs that contain Dexmedetomidine Hydrochloride

1. List of Dexmedetomidine Hydrochloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649296 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
Apr, 2036

(13 years from now)

US9717796 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
Apr, 2036

(13 years from now)

Market Authorisation Date: 21 October, 2015

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

2. List of Igalmi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792246 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(16 years from now)

US11497711 BIOXCEL NA
Jun, 2039

(16 years from now)

US11478422 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(16 years from now)

US11517524 BIOXCEL NA
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 5, 2025

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage

3. List of Precedex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455527 HOSPIRA Methods of treatment using a dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8648106 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US9616049 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8242158 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US10016396 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US9320712 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8338470 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8648106

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

US8242158

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

US8455527

(Pediatric)

HOSPIRA Methods of treatment using a dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

US8338470

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

US9320712

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

US9616049

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

Market Authorisation Date: 17 December, 1999

Treatment: Use for sedation

Dosage: INJECTABLE;INJECTION

How can I launch a generic of PRECEDEX before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic